Key result
Oral low-dose hydromorphone successfully relieved refractory dyspnea and improved the overall condition in a patient with stage D heart failure and renal dysfunction.
Why the study?
Patients with advanced heart failure often suffer from refractory symptoms like dyspnea, requiring palliative care approaches.
Does oral hydromorphone improve refractory dyspnea in a patient with stage D heart failure?
Case Report (n=1)
No
Does oral hydromorphone improve refractory dyspnea in a patient with stage D heart failure?
Oral low-dose hydromorphone may be a helpful agent for treating refractory dyspnea in patients with stage D heart failure and renal dysfunction.
May support oral hydromorphone for refractory dyspnea in stage D HF with renal dysfunction; hypothesis-generating and requires prospective confirmation before practice change.
Patients with advanced heart failure often experience dyspnea, fatigue, edema, and appetite loss. If these symptoms are refractory to treatment, palliative care via a team approach is necessary. We describe a patient with stage D heart failure whose dyspnea and overall condition improved with comprehensive medical treatments including conventional medications for heart failure, continuous infusions of catecholamine and diuretic, and oral hydromorphone. A 67-year-old man with a 12-year history of dilated cardiomyopathy was admitted to our hospital due to exacerbation of heart failure. Despite continuous infusion of catecholamine and diuretic, his dyspnea and liver and renal function continued to worsen. Oral hydromorphone was administered to relieve his refractory dyspnea, which also improved his conditions, continuous infusion of the catecholamine and diuretic could withdraw. Oral low-dose hydromorphone used in the present case might be a helpful agent for treating dyspnea in stage D heart failure patients with renal dysfunction.
No takes yet. Share an insight, caveat, or question.
Nakamura et al. (2021) conducted a case report in Stage D heart failure (n=1). Oral hydromorphone was evaluated on Symptom relief (dyspnea). Oral low-dose hydromorphone successfully relieved refractory dyspnea and improved the overall condition in a patient with stage D heart failure and renal dysfunction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: